OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

From todays : MAIL ON SUNDAY

'Shares in Oxford Biomedica were down 2p to 28p last week, but Friday saw heavy trading as speculators snapped up the shares. The city rumour-mill went into overdrive late last week over a tale that Oxford was about to receive a bid from a US group, possibly Johnson & Johnson. Gossips suggested a price of 50p or more.'

50p here we come

Looking good.

Maybe it's time to sell a few.

Yep, I've sold a chunk.

Contrarian stategy :-)

You maybe right, as takeover spec in my experience is usually hogwash and the price falls after nothing happens, but hope it's not just that, I think it should be rising without talk of a bid.

Maybe sp should be rising - and the "Bid Rumour" is someone trying to rationalise why the sp has risen - well it's quite simple it's risen because people are buying. What we need to know is if the amounts indicate Institutional buying as I understood there has been a round of conferences with the City - and OXB was part of that.(During April05?)
I'm not entirely clear if this is exclusively City-types (as I suspect) but in all probability the Company is not telling them anything much that isn't already released to the Market. It's just that it will be nicely wrapped up and Prof AK is very good at doing that.
/
If "what the company claims" is true, then investors are sitting on a potential cash generator - OXB has plenty of funds so won't need a begging-bowl - this means that Institutions need to get their shares before further rise.....and maybe this is what has happened.
Punters:
Anyone selling "now" believing this rise is Rumour will find it doesn't fall back (well maybe 5%) and will kick themselves for not holding their nerve. That's what I'm doing; although I'll admit there is a temptation: However, my timing is often poor, so why risk the big day? It's not as though the company has been a serial disapointment - they have always done what they said - OK they've been slow, but reward is like that I guess. Fingers crossed.

Appears to be good news so why is the sp down?

Sp starting to recover - clearly there are some holders who are prepared to sell into good news:

LONDON (AFX) - Oxford Biomedica PLC said pre-clinical trials of RetinoStat concluded the treatment for loss of vision may be effective in alleviating cases of age-related macular degeneration (AMD).

Macular degeneration is a retinal degenerative disease that causes progressive loss of central vision, and is the most common cause of vision loss in individuals over the age of 55. Wet AMD accounts for about 10 pct of cases, but is responsible for 90 pct of severe vision loss.

AMD is caused by abnormal blood vessel growth in the eye, leading to distortion and loss of central vision. RetinoStat uses a LentiVector system to deliver genes to the retina that block the formation of new blood vessels which cause the ailment.

The pre-clinical data to be presented by the company in Florida today show RetinoStat was well tolerated and achieved the two efficacy endpoints. Importantly, the results show a statistically significant improvement in reducing the area of abnormal blood vessel growth and blood vessel leakage occurring in cases of wet AMD.

Around 15 million people in the US have some form of AMD, with 1.6 million experiencing wet AMD. Presently, over 500,000 people worldwide lose their sight annually from the disease.

In the second half of 2005, Oxford BioMedica expects to complete additional pre-clinical efficacy studies and prepare for clinical trials, pencilled in to start 2006-07.

'RetinoStat is meeting its design objectives and is on track for clinical development,' chief executive Professor Alan Kingsman said. 'AMD is a devastating disease and there is a real unmet need for a long-lasting efficacious product.'

At 8.00 am shares in Oxford Bio were unchanged at 29-1/2 pence, valuing the Oxford University spin-out at 111 mln stg.

ab/har

Bugger! Wrong again.

Cheer up pachandl,

it's up again today!

so I may sell another chunk.

I risk missing out on a proportion of my profit but heck this share has got a track record of falling back so I'll get another chance & I've still got plenty of these shares left.

Best of luck Apple - tell me after you have sold and I will take out a massive short to get the sp down for you to re-enter. All part of the service.

My finger was hovering over the button but I didn't do it today.

:-)

Collusion eh?
A bit of OUTSIDER price fixing.
Is it legal?

Apple - you need an edge or you will lose money. Outsider dealing? Hmmm, seems legal as far as I see it, otherwise all fund managers would be in prison by now. Have a great weekend.

nice tick up today, anybody with a reason why???? cant find any news on OXB

Just had a look on the uk.biz.yahoo.com website
for information on OXB. Apparently the Broker,
Panmure has placed a 'buy'recommendation on the
stock last week with a 45p price target.

Life is wonderful ya get me!

1704
yeah life is wonderful apart from i may have to sell these babies in a couple of weeks due to house move and raising capital. however, i have made a tidy profit so cant complain. just wish i could stay for the longhaul.

accord
Not sure whats up with MoneyAM's news feed, but here's
todays RNS.


RNS Number:0160M
Oxford Biomedica PLC
09 May 2005


FOR IMMEDIATE RELEASE 9 MAY 2005


OXFORD BIOMEDICA RECEIVES EUROPEAN PATENT FOR TROVAX(R) COVERING 5T4 TUMOUR
ANTIGEN-TARGETED IMMUNOTHERAPY

Oxford, UK: 9 May 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, today announced that the European Patent Office has granted a key
patent (No. EP1036091), that provides broad protection for Oxford BioMedica's
lead product, TroVax. This is one of several granted and pending patents that
protect the Company's ownership of the 5T4 tumour antigen. The granted patent
covers immunotherapy products directed against 5T4 and includes specific claims
to the use of viral delivery systems in 5T4-targeted vaccines.

5T4 is a tumour associated antigen that is expressed on a wide range of tumour
types. A number of published immunohistochemical studies have demonstrated that
there is a high incidence of 5T4 expression on colorectal cancer, renal cell
carcinoma and breast cancer, amongst others. 5T4 expression is frequently
correlated with poor prognosis and metastatic spread. Overall, 5T4 is present on
more than 75% of human solid tumours, yet it is not found on any essential
organs. These characteristics make 5T4 an ideal target for immunotherapy
treatment in a wide range of cancer types.

Commenting on the issued patent Oxford BioMedica's Chief Executive, Professor
Alan Kingsman said: "The newly granted patent, together with several other
granted and pending patents, provide protection for our lead product, TroVax, as
well as next generation cancer vaccines based on the 5T4 antigen. This positions
Oxford BioMedica as one of the leading players in the emerging field of cancer
immunotherapy. TroVax has potential utility as a treatment for most solids
tumours, hence, the potential to be a major commercial opportunity for the
Company."

-Ends-

FILTHY POOR: i thank you, good news is better than none at all.

Thanks FILTHY POOR

Going well so far today!

I nearly sold a few more last Friday, glad I didn't.

Looks too good to be true though.